Loading stock data…
Amphastar Pharmaceuticals (AMPH)
$18.72-0.15 (-0.79%)
Market ClosedLast close Jul 24
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amphastar Pharmaceuticals, Inc. in the Healthcare sector is trading at $18.72 with a market capitalization of $888M. Wall Street consensus targets $22.00 (6 analysts), implying a +17.5% move over the next 12 months. The stock is currently near its 52-week low of $16.65, remaining 18.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +17.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $171.17M↓ | $183.10M↓ | $191.84M↑ | $174.41M↑ | $170.53M |
| Gross Profit | $70.32M↓ | $85.67M↓ | $98.65M↑ | $86.49M↑ | $85.25M |
| Operating Income | $13.63M↓ | $35.61M↑ | $25.32M↓ | $42.18M↑ | $37.29M |
| Net Income | $6.42M↓ | $24.43M↑ | $17.35M↓ | $31.03M↑ | $25.29M |
Peer Comparison
JNJUNHPFE
Fundamentals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$887.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.24%
Volume
Today's trading volume
429,110
Recent News
3 Stocks Under $50 We Keep Off Our Radar
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
1 of Wall Street’s Favorite Stocks to Research Further and 2 Facing Challenges
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
Investing.com -- Bank of America downgraded four U.S. biopharmaceutical companies, lowering ratings on Alkermes, Amphastar Pharmaceuticals and Biohaven to Underperform, while cutting Liquidia to Neutral, citing a combination of stretched valuations, uncertain near-term catalysts and a rebalancing of its ratings across the sector.
New Strong Sell Stocks for June 23rd
ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.